171 related articles for article (PubMed ID: 19911123)
1. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment.
Sweeney CJ; Takimoto C; Wood L; Porter JM; Tracewell WG; Darwish M; D'Andrea DM; Remick SC
Cancer Chemother Pharmacol; 2010 Jul; 66(2):345-56. PubMed ID: 19911123
[TBL] [Abstract][Full Text] [Related]
2. Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective.
Lin CJ; Wu MH; Hsueh YM; Sun SS; Cheng AL
Cancer Chemother Pharmacol; 2005 Feb; 55(2):170-8. PubMed ID: 15322825
[TBL] [Abstract][Full Text] [Related]
3. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Wang Z; Zhou J; Lu X; Gong Z; Le XC
Chem Res Toxicol; 2004 Jan; 17(1):95-103. PubMed ID: 14727923
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide.
Fujisawa S; Ohno R; Shigeno K; Sahara N; Nakamura S; Naito K; Kobayashi M; Shinjo K; Takeshita A; Suzuki Y; Hashimoto H; Kinoshita K; Shimoya M; Kaise T; Ohnishi K
Cancer Chemother Pharmacol; 2007 Mar; 59(4):485-93. PubMed ID: 16937107
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
[TBL] [Abstract][Full Text] [Related]
6. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
[TBL] [Abstract][Full Text] [Related]
7. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies.
Kumana CR; Au WY; Lee NS; Kou M; Mak RW; Lam CW; Kwong YL
Eur J Clin Pharmacol; 2002 Nov; 58(8):521-6. PubMed ID: 12451429
[TBL] [Abstract][Full Text] [Related]
8. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
9. A phase I study to study arsenic trioxide with radiation and hyperthermia in advanced head and neck cancer.
Huilgol NG
Int J Hyperthermia; 2006 Aug; 22(5):391-7. PubMed ID: 16891241
[TBL] [Abstract][Full Text] [Related]
10. Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
Zhao Q; Guo M; Hostetter TH; Chen H; Lin L; Hai X
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1173-1182. PubMed ID: 34181499
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
Berenson JR; Boccia R; Siegel D; Bozdech M; Bessudo A; Stadtmauer E; Talisman Pomeroy J; Steis R; Flam M; Lutzky J; Jilani S; Volk J; Wong SF; Moss R; Patel R; Ferretti D; Russell K; Louie R; Yeh HS; Swift RA
Br J Haematol; 2006 Oct; 135(2):174-83. PubMed ID: 17010047
[TBL] [Abstract][Full Text] [Related]
12. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
13. Uptake of inorganic and organic derivatives of arsenic associated with induced cytotoxic and genotoxic effects in Chinese hamster ovary (CHO) cells.
Dopp E; Hartmann LM; Florea AM; von Recklinghausen U; Pieper R; Shokouhi B; Rettenmeier AW; Hirner AV; Obe G
Toxicol Appl Pharmacol; 2004 Dec; 201(2):156-65. PubMed ID: 15541755
[TBL] [Abstract][Full Text] [Related]
14. Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure.
Pu YS; Yang SM; Huang YK; Chung CJ; Huang SK; Chiu AW; Yang MH; Chen CJ; Hsueh YM
Toxicol Appl Pharmacol; 2007 Jan; 218(2):99-106. PubMed ID: 17196235
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide associated toothache.
Siderov J; Duggan J
J Oncol Pharm Pract; 2010 Jun; 16(2):127-8. PubMed ID: 19525303
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).
Bajorin DF; Halabi S; Small E
Clin Genitourin Cancer; 2009 Oct; 7(3):E66-70. PubMed ID: 19815484
[TBL] [Abstract][Full Text] [Related]
17. Arsenic metabolism in multiple myeloma and astrocytoma cells.
Falnoga I; Slejkovec Z; Pucer A; Podgornik H; Tusek-Znidaric M
Biol Trace Elem Res; 2007 Apr; 116(1):5-28. PubMed ID: 17634624
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients.
Zheng WL; Zhang GS; Xu YX; Shen JK; Dai CW; Pei MF
Leuk Res; 2008 Feb; 32(2):251-4. PubMed ID: 17920679
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia.
Ni J; Chen G; Shen Z; Li X; Liu H; Huang Y; Fang Z; Chen S; Wang Z; Chen Z
Chin Med J (Engl); 1998 Dec; 111(12):1107-10. PubMed ID: 11263375
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
